Immunic, Inc. (IMUX), Tuesday announced the appointment of Michael Panzara, as Chief Medical Officer, succeeding Andreas Muehler, effective April 24, 2026.
In this new role, he will lead the company's development organization, including clinical development, medical affairs, and regulatory affairs, and will be a critical partner to the CEO and the Board of Directors in defining and driving the overall company strategy.
Panzara most recently served as Chief Medical Officer of Neurvati Neurosciences, Inc.
In light of his appointment, the Compensation Committee of Immunic's Board of Directors granted Panzara an initial equity option to purchase 300,000 shares of common stock of the company under the Immunic, Inc. 2026 Inducement Equity Compensation Plan.
In the pre-market hours, IMUX is trading at $9.70, down 2.81 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.